Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Fee Cut Rule Needs Review before Debate on Annual NHI Price Revisions: MHLW Exec
December 4, 2014
- LDP Members Share Various Opinions on Social Security Issues
December 4, 2014
- Council Approves Subsidies for Retreatment with 3-Drug Combination Therapies Using Protease Inhibitors Other than Simeprevir
December 4, 2014
- ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
- Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
December 3, 2014
- Kyowa Kirin’s Poteligeo to Receive Additional Indication for Incipient Untreated ATL, Will Be Added to mLSG15 Therapy
December 2, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 17 - 28
December 1, 2014
- PAFSC’s Second Committee Backs Approval of Novartis’s Secukinumab
December 1, 2014
- Japan’s 1st Orphan Regenerative Medicine Status Given to Skin-Derived Cell Sheet
December 1, 2014
- 13 APIs/23 Products Including Remicade Biosimilar Added to NHI Price List
November 28, 2014
- MHLW Warns of Hyperbilirubinemia in Patients on Sovriad
November 27, 2014
- Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research
November 27, 2014
- Cabinet OKs Regenerative Medicine Guidelines
November 26, 2014
- New Pharma Law Takes Effect to Up the Ante for Safety
November 26, 2014
- Debates on Yearly NHI Price Cuts Put on Hold as Attention Turns to Election
November 26, 2014
- Chuikyo OKs Requirements for Hospitals Offering Mixed Care in Economic Zones
November 25, 2014
- MHLW Designates 6 APIs as Orphan Drugs
November 25, 2014
- PAFSC First Committee Backs Approval of Takeda’s Vonoprazan
November 25, 2014
- IGDRP to Extend Activities for 2 More Years with Aim of Harmonizing Generic Drug Review
November 25, 2014
- MHLW Orders Revision of Package Insert for Reminyl
November 25, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…